LCI Profile
Lannett Company, Inc., headquartered in Trevose, Pennsylvania, is a prominent player in the pharmaceutical industry specializing in the development, manufacturing, packaging, marketing, and distribution of generic versions of brand-name pharmaceutical products within the United States. Established in 1942, the company operates with a focus on delivering a diverse range of pharmaceutical solutions across various therapeutic areas.
The company's extensive product portfolio includes solid oral and extended-release formulations, as well as topical, liquid, nasal, oral solution, ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, injectable, and oral dosage forms. These products cater to a wide spectrum of medical indications such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory, allergy, cough, cold, urinary disorders, and other medical conditions.
Among its notable offerings are Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, Verapamil SR tablets, and Numbrino nasal solution. Lannett distributes its pharmaceutical products through a wide-ranging network including generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.
In addition to its robust product offerings, Lannett Company, Inc. has established strategic supply and development agreements with leading entities in the pharmaceutical sector such as Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other key industry players. These collaborations underscore Lannett's commitment to expanding its market presence and enhancing its capabilities in delivering high-quality and cost-effective pharmaceutical solutions to meet the evolving needs of healthcare providers and patients alike.
|
